Application of pseudomonas aeruginosa vaccine in respiratory disease

Abstract

The present invention provides use of a Pseudomonas aeruginosa vaccine in the manufacture of a medicament for the prevention and treatment of respiratory system disease. The Pseudomonas aeruginosa vaccine of the present invention can effectively prevent and treat pulmonary infection caused by multidrug-resistant Pseudomonas aeruginosa and COPD complicated with Pseudomonas aeruginosa infection by activating the specific immune response of the body. The Pseudomonas aeruginosa vaccine of the present invention can reduce the bacterial load in the immunized subject through the established immunization procedures, thereby providing a technical solution that can effectively prevent pulmonary infection with Pseudomonas aeruginosa, which avoids the technical problems caused by the use of antibiotics such as poor effectiveness, difficulty in curing and proneness to drug resistance in the prior art to a certain degree.

1 . Use of a  Pseudomonas aeruginosa  vaccine in the manufacture of a medicament for the prevention and treatment of respiratory system disease, wherein the respiratory system disease is chronic pulmonary insufficiency complicated with bacterial infection, the chronic pulmonary insufficiency is chronic obstructive pulmonary disease and the bacterial infection is  Pseudomonas aeruginosa  infection; wherin the  Pseudomonas aeruginosa  vaccine comprises inactivated  Pseudomonas aeruginosa  and  Pseudomonas aeruginosa  member visicles, the inactivated  Pseudomonas aeruginosa  is inactivated by irradiation, and the  Pseudomonas aeruginosa  member vesicles are isolated from the  Pseudomonas aeruginosa  inactivated by irradiation. 
     
     
         2 . The use according to  claim 1 , wherein the respiratory system disease comprises primary respiratory system disease and secondary respiratory system disease. 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . The use according to  claim 14 , wherein the chronic obstructive pulmonary disease comprises chronic bronchitis and emphysema. 
     
     
         6 . The use according to  claim 14 , wherein the chronic obstructive pulmonary disease is acute exacerbation of chronic obstructive pulmonary disease. 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . The use according to  claim 1 , wherein immunization procedure of the  Pseudomonas aeruginosa  vaccine comprises: injection take places at (i) 0, 3rd, and 7th days; (ii) 0, 1st, and 2nd weeks; and (iii) 0, 2nd, and 4th weeks. 
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . The use according to  claim 1 , wherein the  Pseudomonas aeruginosa  vaccine prevents  Pseudomonas aeruginosa  infection, and reduces bacterial load in the respiratory system disease. 
     
     
         13 . The use according to  claim 1 , wherein content of whole-cell  Pseudomonas aeruginosa  in the  Pseudomonas aeruginosa  vaccine comprises: 1×10 4 -1×10 11 /injection. 
     
     
         14 . The use according to  claim 13 , wherein the content of the whole-cell  Pseudomonas aeruginosa  in the  Pseudomonas aeruginosa  vaccine comprises: 1×10 4 /injection, 1×10 5 /injection, 1×10 6 /injection, 1×10 7 /injection, 1×10 8 /injection, 1×10 9 /injection and 1×10 11 /injection. 
     
     
         15 . The use according to  claim 1 , wherein the  Pseudomonas aeruginosa  vaccine further contains an immunoadjuvant. 
     
     
         16 . The use according to  claim 15 , wherein the immunoadjuvant is aluminum hydroxide. 
     
     
         17 . The use according to  claim 1 , wherein administration site of the  Pseudomonas aeruginosa  vaccine is subcutaneous, muscle and/or mucosa. 
     
     
         18 . The use according to  claim 1 , wherein the medicament can also contain any pharmaceutically acceptable carrier and/or adjuvant. 
     
     
         19 . The use according to  claim 18 , wherein the carrier is a liposome. 
     
     
         20 . A pharmaceutical composition for treating respiratory system disease, wherein comprising a  Pseudomonas aeruginosa  vaccine and at least one antibiotic, wherein the at least one antibiotic is aztreonam, the  Pseudomonas aeruginosa  vaccine comprises inactivated  Pseudomonas aeruginosa  and/or  Pseudomonas aeruginosa  membrane vesicles; wherein the inactivated  Pseudomonas aeruginosa  is inactivated by irradiation, and the  Pseudomonas aeruginosa  membrane vesicles are isolated from the  Pseudomonas aeruginosa  inactivated by irradiation. 
     
     
         21 . (canceled) 
     
     
         22 . (canceled)